GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » Change In Receivables

Neurobiological Technologies (Neurobiological Technologies) Change In Receivables : $-2.82 Mil (TTM As of Sep. 2009)


View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies Change In Receivables?

Neurobiological Technologies's change in receivables for the quarter that ended in Sep. 2009 was $-2.82 Mil. It means Neurobiological Technologies's Accounts Receivable increased by $2.82 Mil from Jun. 2009 to Sep. 2009 .

Neurobiological Technologies's change in receivables for the fiscal year that ended in Jun. 2009 was $0.42 Mil. It means Neurobiological Technologies's Accounts Receivable declined by $0.42 Mil from Jun. 2008 to Jun. 2009 .

Neurobiological Technologies's Accounts Receivable for the quarter that ended in Sep. 2009 was $3.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Neurobiological Technologies's Days Sales Outstanding for the three months ended in Sep. 2009 was 45.43.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Neurobiological Technologies's liquidation value for the three months ended in Sep. 2009 was $28.08 Mil.


Neurobiological Technologies Change In Receivables Historical Data

The historical data trend for Neurobiological Technologies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies Change In Receivables Chart

Neurobiological Technologies Annual Data
Trend Jun00 Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 -5.55 5.12 -0.17 0.42

Neurobiological Technologies Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 -0.02 -0.03 0.05 -2.82

Neurobiological Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurobiological Technologies  (OTCPK:NTII) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Neurobiological Technologies's Days Sales Outstanding for the quarter that ended in Sep. 2009 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=3/6.026*91
=45.43

2. In Ben Graham's calculation of liquidation value, Neurobiological Technologies's accounts receivable are only considered to be worth 75% of book value:

Neurobiological Technologies's liquidation value for the quarter that ended in Sep. 2009 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=26.489-0.655+0.75 * 3+0.5 * 0
=28.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurobiological Technologies Change In Receivables Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurobiological Technologies (Neurobiological Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583
Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.
Executives
Ariel Warszawski 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp 10 percent owner 426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp 10 percent owner FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin director
Abraham E Cohen director 500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer director HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc other: Direct Beneficial Owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines